Every material Form 8-K DocGo Inc. has filed with the SEC since July 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
DocGo reported third-quarter 2026 revenue of $73.4 million, up from $70.8 million a year earlier, and a net loss of $18.1 million, narrower than the $29.7 million loss in the prior-year quarter. The company cut its full-year 2026 revenue guidance to approximately $300 million from $305-$310 million, and its board began a CEO search as CEO Lee Bienstock's employment contract expires on December 31, 2026.
Q3 2026 revenue was $73.4 million, compared with $70.8 million in Q3 2025.
Q3 2026 net loss was $18.1 million, compared with $29.7 million in Q3 2025; adjusted EBITDA was a loss of $3.2 million, compared with a loss of $7.2 million.
Full-year 2026 revenue guidance was lowered to approximately $300 million from $305-$310 million; full-year adjusted EBITDA guidance of a $17-$22 million loss was unchanged.
Lee Bienstock's contract expires December 31, 2026; he will remain as CEO through at least March 31, 2027 while the board searches for a successor.
DocGo and its subsidiaries entered into an amended and restated credit agreement on October 1, 2026, with Perceptive Credit Holdings IV as administrative agent, replacing a prior Citibank-led revolving facility that was terminated the same day. The new term loans total $102 million in committed facilities, with a stated maturity of December 6, 2029, and the company issued a warrant for 4,000,000 shares at $0.5039 per share as part of the deal, which could dilute existing holders.
Term loans include $52 million continued from prior debt, $12.5 million new Term Loan B, $12.5 million Term Loan C tied to the Merger, and $25 million delayed draw Term Loan D
Term SOFR with a 3.50% floor plus a 7.50% margin; maturity December 6, 2029
Warrant to purchase 4,000,000 common shares at $0.5039 per share, fully vested, exercisable through the tenth anniversary of October 1, 2026
Ambulnz began managing Hicuity's non-clinical operations effective October 1, 2026; 98,992,347 common shares were outstanding as of October 1, 2026
DocGo signed a merger agreement on August 16, 2026 to acquire virtual care provider Hicuity Health, with Hicuity becoming a wholly owned subsidiary, subject to closing conditions. The same day it reported second-quarter 2026 results showing lower revenue, a wider net loss, and a lower full-year adjusted EBITDA outlook, which weigh on shareholders.
Q2 2026 revenue was $73.4 million, down from $80.4 million a year earlier; migrant-related programs contributed $18.8 million in Q2 2025 and none in Q2 2026.
Q2 2026 net loss was $18.0 million, versus $13.3 million in Q2 2025; adjusted EBITDA was ($6.3) million, versus ($6.1) million.
Full-year 2026 adjusted EBITDA guidance is now ($17)-($22) million, down from prior guidance of ($5)-($10) million; revenue guidance was narrowed to $305-$310 million from $300-$315 million.
Hicuity's Series F preferred holder would receive the entire merger consideration: 2.0% of DocGo shares plus up to 3.5% in earnout shares; Ambulnz will assume about $52 million of Hicuity debt, and Perceptive Credit Holdings IV has committe
DocGo received a Nasdaq letter on July 28, 2026, granting an additional 180 calendar days, until January 25, 2027, to regain compliance with the minimum bid price requirement. The company's stock must close at or above $1.00 for at least 10 consecutive business days to regain compliance, and the company says it cannot assure it will do so in time. Shareholders should note that the company may pursue a reverse stock split, which stockholders approved at the June 16, 2026 annual meeting.
Nasdaq granted an additional 180 calendar days, until January 25, 2027, to meet the $1.00 minimum bid price requirement
Compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days
Stockholders approved a reverse stock split at ratios of 1-for-5 to 1-for-10 at the June 16, 2026 annual meeting, with the final ratio to be set by the Board
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DocGo Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →